Bioptik Technology Inc

Bioptik Technology Inc maintains a strong liquidity position, with cash and equivalents amounting to TWD 399.3 million, representing 25.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 0.105, indicating a moderate ability to service liabilities from operating cash flows. The current ratio of 1.93 suggests the company can cover its short-term obligations with its current assets. Profitability metrics show a return on equity (ROE) of 7.34% and a return on assets (ROA) of 4.53%, both below the industry median for medical equipment and supplies firms. The gross margin of 29.1% is in line with industry norms, but the operating margin of 8.0% is slightly below the median, indicating potential inefficiencies in cost control or pricing power. The company's revenue is concentrated in two primary segments: medical testing products and beauty care products. While the geographic distribution is not fully disclosed, the company operates in both domestic and overseas markets. The lack of detailed segment revenue data limits the ability to assess exposure to specific regions or product lines. Outlook data indicates a projected revenue growth of 4.2% in the current fiscal year and 3.8% in the next fiscal year. This growth is driven by expansion in overseas markets and product diversification. However, the company's capital expenditure of TWD -22.8 million suggests a focus on cost optimization rather than aggressive expansion. Risk assessment reveals a low liquidity risk and a low dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.4 is conservative, and the company has not issued additional shares in the recent period. However, the company's reliance on a limited number of product lines and brand names could pose a concentration risk if market demand shifts. Recent filings and transcripts do not indicate any material events or strategic shifts. The company's focus remains on maintaining profitability and expanding its product portfolio in both medical and beauty care markets. No significant regulatory or litigation risks were identified in the latest disclosures.